Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023-Reference-Cited by-同舟云学术

Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023

Published:2024-04-25 Issue:17 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Otto-Knapp Ralf¹,Edwards Suzanne²,Kuchukhidze Giorgi³,Kröger Stefan⁴,Häcker Brit¹,Bivol Stela³,Yedilbayev Askar³

Affiliation:

1. German Central Committee against Tuberculosis (DZK), Berlin, Germany

2. Independent Consultant & Department of Healthcare Management, Technical University of Berlin, Berlin, Germany

3. World Health Organization, Regional Office for Europe, Copenhagen, Denmark

4. Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

Abstract

The BPaLM regimen (bedaquiline, pretomanid, linezolid and moxifloxacin) recently recommended by the World Health Organization offers short, safe, and effective treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB). In a survey with national TB focal points in 18 central and western European countries to explore barriers for the implementation of BPaLM, only three reported full availability of pretomanid, a necessary component of this regimen. Implementation barriers included financing and procurement. Solutions on national and supranational level are needed to guarantee universal access.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference14 articles.

1. World Health Organization (WHO). Global tuberculosis report 2023. Geneva: WHO; 2023. Available from: https://iris.who.int/handle/10665/373828

2. International Union Against Tuberculosis and Lung Disease (The Union). TB among refugees from Ukraine in European countries. Paris: The Union; 2024. Available from: https://theunion.org/news/tb-among-refugees-from-ukraine-in-european-countries

3. The impact of the war in Ukraine on the epidemiological situation of tuberculosis in Europe.;Wilczek;J Clin Med,2023

4. World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 2022. Available from: https://iris.who.int/handle/10665/365308

5. Update of drug-resistant tuberculosis treatment guidelines: A turning point.;Vanino;Int J Infect Dis,2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response;Clinical Microbiology and Infection;2024-09

2. Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland;Respiration;2024